Respiratorius AB (publ) (XSAT:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.290
-0.095 (-6.86%)
At close: Mar 3, 2026
-82.57%
Market Cap 10.19M
Revenue (ttm) n/a
Net Income (ttm) -6.95M
Shares Out 7.90M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,844
Average Volume 20,069
Open 1.375
Previous Close 1.385
Day's Range 1.290 - 1.375
52-Week Range 1.190 - 10.500
Beta 1.68
RSI 37.68
Earnings Date Feb 10, 2026

About Respiratorius AB

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company’s products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 0
Stock Exchange Spotlight Stock Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.